Automated classification of patients with chronic lymphocytic leukemia and immunocytoma from flow cytometric three-color immunophenotypes
Related Experiment Video
Updated: Aug 10, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
1Max-Planck-Institute of Biochemistry, Martinsried, Germany. valet@biochem.mpg.de
Insights
Automated flow cytometry analysis accurately distinguishes between chronic lymphocytic leukemia (B-CLL) and other B-cell lymphomas. Standardized classification using CLASSIF1 achieved nearly 100% correct patient identification, optimizing immunophenotype panels.
Area of Science:
- Hematology
- Immunology
- Computational Biology
Background:
- Distinguishing between chronic lymphocytic leukemia (B-CLL) and other low-grade B-cell non-Hodgkin's lymphomas (NHL) is crucial for treatment.
- Traditional flow cytometry methods can be complex and require expert interpretation.
Purpose of the Study:
- To develop and validate an automated flow cytometry analysis method for discriminating B-CLL from other B-cell NHLs.
- To assess the robustness and accuracy of a multiparameter classification program (CLASSIF1) for immunophenotyping.
Main Methods:
- Automated analysis of flow cytometric immunophenotypes from peripheral blood and bone marrow aspirates using CLASSIF1.
- Evaluation of combined lymphocyte, monocyte, and granulocyte (LMG) analysis with standardized triple matrix classifiers.
- Utilized antibody triplets including CD45/14/20, CD4/8/3, kappa/CD19/5, lambda/CD19/5, and CD10/23/19.
Main Results:
- Nearly 100% correct individual patient classification was achieved.
- Manually unclassifiable patients were unambiguously classified by the automated system.
- The lambda/CD19/5 antibody triplet provided information comparable to the full panel, suggesting panel optimization is possible.
- Discriminant information is derived from total antibody binding and ratios, not just cell population frequencies.
Conclusions:
- Automated flow cytometry analysis using CLASSIF1 provides a robust, accurate, and standardized method for classifying B-cell leukemias and lymphomas.
- This approach enhances diagnostic capabilities and allows for optimization of immunophenotyping panels.
- The findings highlight the importance of antibody binding parameters over simple frequency counts for accurate classification.
Abstract:
The goal of this study was the discrimination between chronic lymphocytic leukemia (B-CLL), clinically more aggressive lymphoplasmocytoid immunocytoma (LP-IC) and other low-grade non-Hodgkin's lymphomas (NHL) of the B-cell type by automated analysis of flow cytometric immunophenotypes CD45/14/20, CD4/8/3, kappa/CD19/5, lambda/CD19/5 and CD10/23/19 from peripheral blood and bone marrow aspirate leukocytes using the multiparameter classification program CLASSIF1. The immunophenotype list mode files were exhaustively evaluated by combined lymphocyte, monocyte, and granulocyte (LMG) analysis. The results were introduced into databases and automatically classified in a standardized way. The resulting triple matrix classifiers are laboratory and instrument independent, error tolerant, and robust in the classification of unknown test samples. Practically 100% correct individual patient classification was achievable, and most manually unclassifiable patients were unambiguously classified. It is of interest that the single lambda/CD19/5 antibody triplet provided practically the same information as the full set of the five antibody triplets. This demonstrates that standardized classification can be used to optimize immunophenotype panels. On-line classification of test samples is accessible on the Internet: http://www.biochem.mpg.de/valet/leukaem1.html Immunophenotype panels are usually devised for the detection of the frequency of abnormal cell populations. As shown by computer classification, most the highly discriminant information is, however, not contained in percentage frequency values of cell populations, but rather in total antibody binding, antibody binding ratios, and relative antibody surface density parameters of various lymphocyte, monocyte, and granulocyte cell populations.
